EDEN PRAIRIE, Minn., August 10, 2022 – Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced today that it has appointed Jack Lake, M.D. as the company’s new Medical Director.
Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix’s Medical Director while remaining in his current roles at the University.
“We are excited to have Dr. Lake join the Miromatrix team,” says Dr. Jeff Ross, Miromatrix’s CEO “Dr. Lake brings tremendous experience and knowledge of liver and whole organ transplantation. He is extraordinarily equipped to help us advance our mission of eliminating the transplant waiting list by bioengineering fully functional organs for transplant.”
In addition to his work at the University of Minnesota, Dr. Lake is the past President of both the United Network for Organ Sharing (UNOS) and the American Society of Transplant Physicians. Dr. Lake has also held leadership roles in the American Association for the Study of Liver Disease and the International Liver Transplantation Society. He is also the former editor of the journal Liver Transplantation. Dr. Lake’s research expertise includes liver allocation, predictors of outcomes following liver transplantation and the development of new treatments for patients with liver disease.
“I am very excited to be joining the team at Miromatrix,” says Dr. Lake. “Optimally serving patients with organ failure and in need of organ transplantation has been my passion for my entire career. I truly believe that Miromatrix’s technology has the promise to better serve an even greater number of patients with organ failure.”
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
